The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

With a range of treatments available for presbyopia, the challenge for clinicians is to guide patients toward the most ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

A novel DIPN method enhances GA segmentation by integrating ConvLSTM, projection attention, adaptive pooling, and contrastive ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.